Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1983 1
1984 3
1988 2
1991 1
1993 3
1994 2
1995 2
1996 4
1997 3
1998 5
1999 4
2000 2
2001 8
2002 7
2003 2
2004 5
2005 9
2006 6
2007 5
2008 7
2009 5
2010 7
2011 9
2012 18
2013 13
2014 21
2015 24
2016 31
2017 26
2018 28
2019 31
2020 26
2021 24
2022 28
2023 28
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Diabetic neuropathy.
Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Feldman EL, et al. Among authors: bril v. Nat Rev Dis Primers. 2019 Jun 13;5(1):42. doi: 10.1038/s41572-019-0097-9. Nat Rev Dis Primers. 2019. PMID: 31197183 Free PMC article.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Among authors: bril v. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Diabetic neuropathy.
Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Feldman EL, et al. Among authors: bril v. Nat Rev Dis Primers. 2019 Jun 13;5(1):41. doi: 10.1038/s41572-019-0092-1. Nat Rev Dis Primers. 2019. PMID: 31197153 Review.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Treatment Approaches for Atypical CIDP.
Menon D, Katzberg HD, Bril V. Menon D, et al. Among authors: bril v. Front Neurol. 2021 Mar 15;12:653734. doi: 10.3389/fneur.2021.653734. eCollection 2021. Front Neurol. 2021. PMID: 33790853 Free PMC article. Review.
359 results